Our Science

Our approach starts with identifying evolutionary T cell adaptations found within human biology, resulting in increased T cell proliferation, persistence, and function.

We have developed a suite of proprietary potency enhancement technologies that have the potential to address various challenges that have limited the ability of adoptive T cell therapies to treat solid tumors.

Our Science

the challenge T cell therapies face numerous barriers to success in solid tumors

To effectively treat solid tumors, adoptive T cells must overcome multiple obstacles, including poor T cell proliferation and persistence, T cell exhaustion, limited T cell infiltration of the tumor, and the immunosuppressive tumor microenvironment.

Our approach Enhance T cell therapies with genetic events
pre-selected by cancer evolution

Moonlight’s founders examined a series of ‘experiments of nature’ – T cell disease states and their underlying mutations – compiling a library of genetic events identified in T cells. They hypothesized that the T cell mutations they had identified evolved as a result of the same selective pressures facing anti-tumor therapeutic T cells. Indeed, under similar selective pressures that therapeutic T cells may encounter while confronting tumors, the candidate gene variants uncovered dramatically increase the potency of T cells targeting a variety of tumors in model systems.

1Sequence dominant T cell clones from humans
2Generate libraries of diverse mutation types
3Screen for mutations with favorable profiles
4Develop cell therapies with evolution-backed enhancement

Our Science

how we are different Leveraging the full spectrum of genetic adaptations evolved in human T cells

Others have focused on increasing/decreasing expression of wild-type genes or developing synthetic genes to address the challenges of targeting solid tumors. In contrast, we are exploring a wide range of genetic adaptations that selectively evolve in T cells in humans and under conditions that mimic tumor microenvironments. We then deliver these adaptations to therapeutic T cells to supercharge their attack on tumors.